Get started
Author

Raquel Marse Fabregat

Observed names: Marsé Fabregat, Raquel, R. Marse Fabregat, R. Marse-Fabregat, R. MarsÉ Fabregat, R. Marsé, R. Marsé Fabregat, Raquel Marsé, Raquel Marsé Fabregat, Raquel Marsé-Fabregat
ORCID: 0000-0001-6487-7483
Observed ORCID: 0000-0001-6487-7483
OpenAlex ID: A5073486032
Atezolizumab Plus Bevacizumab as First-line Treatment for Patients With Metastatic Nonsquamous Non–Small Cell Lung Cancer With High Tumor Mutation Burden: A Nonrandomized Controlled Trial
2022 · Mariano Provencio, Ana Laura Ortega, et al. · JAMA Oncology · 55
PDF
What do patients and oncologists think about the evaluation and management of cancer-related anorexia-cachexia? The Quasar_SEOM study
2023 · Yolanda Escobar, Avinash Ramchandani, et al. · Clinical & Translational Oncology · 6
PL03.10 Adjuvant Chemotherapy (CT) vs CT-immunotherapy for R0 Stage IB-IIIA NSCLC Patients (NADIM ADJUVANT): a Randomized, Phase 3 Trial
2025 · M. Provencio, R. Bernabé, et al. · Journal of Thoracic Oncology · 5
Increased Quality of Life in Patients with Breakthrough Cancer Pain after Individualized Therapy: the CAVIDIOM Study
2022 · Paula González Villarroel, Josep Gumà Padró, et al. · Future Oncology · 5
1408P Differences on immune biomarkers between KRAS G12C and KRAS non-G12C mutated non-small cell lung cancer
2023 · L. Masfarre Pinto, A.S.D.F.M. Parreira, et al. · Annals of Oncology · 2
PDF
Real-World Insights into Stage I–III Non-Small Cell Lung Cancer in Spain in the Pre-Immunotherapy Era Using AI Techniques: The IntellyLUNG Study
2026 · Jesús Corral Jaime, Javier de Castro, et al. · Life · 1
PDF
1284P Clinical utility of liquid biopsy for non-small cell lung cancer patients with ALK fusion variants treated with brigatinib
2024 · L. Robado de Lope, M.R. García Campelo, et al. · Annals of Oncology · 1
55P Differences in response to immune treatment between KRAS G12C and KRAS non-G12C mutated non-small cell lung cancer
2024 · L. Masfarre Pinto, A.S. De Freitas Matos-Parreira, et al. · ESMO Open · 1
1010P Assessment of early resistance mechanisms to first-line osimertinib in EGFR-mutant NSCLC using spatial transcriptomics
2022 · G. Ruiz de Garibay, B. Roch, et al. · Annals of Oncology · 1
PDF
NORA trial (GECP 15/02): First efficacy results of the Spanish Lung Cancer Group (SLCG) phase II trial of concurrent chemo-radiotherapy (CT-RT) with cisplatin (P) plus metronomic oral vinorelbine (mOV) for unresectable locally advanced non-small cell lung cancer (LA-NSCLC).
2018 · Dolores Isla, Margarita Majem, et al. · Journal of Clinical Oncology · 1
Clinical activity of afatinib in a cohort of patients with lung adenocarcinoma harbouring uncommon EGFR mutations: A Spanish retrospective multicentre study.
2018 · Manuel Domine, Victor Diaz, et al. · Journal of Clinical Oncology · 1
Randomized phase II trial (RENO): Efficacy results of oral vinorelbine or etoposide combined with cisplatin in chemo-radiotherapy treatment of locally advanced NSCLC (LA-NSCLC)—SLCG 10/02.
2016 · Mariano Provencio, Ramon de las Penas, et al. · Journal of Clinical Oncology · 1
Inflammatory circulating biomarkers in non-small cell lung cancer: profile description and survival assessment
2026 · L. ValiÑa Amado, E. Martínez Font, et al. · Clinica Chimica Acta
Clinical outcomes of KRAS G12C versus non-G12C mutant NSCLC treated with immunotherapy: a multicentre real-world study
2026 · Laura Masfarré, Ana Sofia Parreira, et al. · Lung Cancer
PDF
Spatial transcriptomic profiling to identify stroma-based prognostic groups in oncogene-addicted lung cancer.
2026 · Helena Bote-de Cabo, Adrian Portillo, et al. · Journal of Clinical Oncology
Osimertinib plus repotrectinib phase I trial in TKI-resistant non-small cell lung cancer (NSCLC) with EGFR mutations.
2025 · Andrés Aguilar Hernandez, Manuel Cobo, et al. · Journal of Clinical Oncology
PDF
256P: 2-year survival outcomes of atezolizumab plus bevacizumab as first-line treatment for patients with metastatic nonsquamous non–small cell lung cancer with high tumor mutation burden: TELMA trial final report
2025 · M. Provencio Pulla, A.L.O. Ortega Granados, et al. · Journal of Thoracic Oncology
PDF
164P A spatially informed transcriptomic model to forecast early resistance to front-line osimertinib in advanced EGFR-mutant NSCLC
2024 · J. Zugazagoitia, G. Ruiz de Garibay, et al. · Annals of Oncology
PDF
P2.16-02 Pembrolizumab, Lenvatinib and Chemotherapy Combination in First Line Extensive-Stage Small Cell Lung Cancer: PEERS Phase 2 Trial
2023 · N. Reguart Aransay, I. Victoria, et al. · Journal of Thoracic Oncology
PDF
Guia itinerari formatiu tipus de l'especialitat d'oncologia mèdica (2023-2024)
2023 · Marsé Fabregat, Raquel, Luna Fra, Pablo, et al. · Docusalut (Conselleria de Salut i Consum del Govern de les Illes Balears)
Survival outcomes in ALK-positive NSCLC patients (p) treated 1st line brigatinib and impact of the ALK fusion variant.
2023 · Mariano Provencio-Pulla, Rosario Garcia Campelo, et al. · Journal of Clinical Oncology
PDF
P1.15-09 First-line Atezolizumab plus Bevacizumab for Metastatic High-Intermediate TMB in Non-squamous NSCLC. The TELMA Study.
2022 · M. Provencio-pulla, A.L. Ortega, et al. · Journal of Thoracic Oncology
PDF
NORA trial (GECP 15/02): Updated results of the Spanish Lung Cancer Group (SLCG) phase II trial of concurrent chemo-radiotherapy (CT-RT) with cisplatin (P) plus metronomic oral vinorelbine (mOV) for unresectable locally advanced non-small cell lung cancer (LA-NSCLC)
2019 · M. Guirado, M. Majem, et al. · Annals of Oncology
P1.01-93 Metastases Sites as a Prognostic Factor in a Real-World Multicenter Cohort Study of Spanish ALK-Positive NSCLC Patients (p)
2019 · L. Angelats, R. Garcia Campelo, et al. · Journal of Thoracic Oncology
PDF
Effect of central nervous system (CNS) metastases in a real-world multicenter cohort study of Spanish ALK-positive non-small cell lung cancer (NSCLC) patients (p)
2019 · L. Angelats, M.R. Garcia Campelo, et al. · Annals of Oncology
Works count: 28
Citation count: 80
H-index: 4
I10-index: 1
Year
Topic
Type